BioAtla grants BioMotiv exclusive worldwide rights to IL-22 antibody for inflammatory bowel disease and colorectal cancer

SAN DIEGO, Calif. and CLEVELAND, Ohio – February 19, 2014 – BioAtla, a global biotechnology company focused on the development of conditionally active biologics (CABs), and BioMotiv, the therapeutics accelerator for The Harrington Project for Discovery & Development, today announced that BioAtla licensed exclusive worldwide rights to BioMotiv to develop and commercialize its Th22 pathway directed antibody compound for the treatment of inflammatory bowel diseases (IBD) and oncologic indications. In conjunction with the agreement, BioMotiv established Kodosil Bio which will develop all compounds resulting from the license.

Read more here